http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012520307-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2012520307-A |
| titleOfInvention | Pyrrolo [2,3-B] pyridine derivatives for inhibition of RAF kinase |
| abstract | Propane-1-sulfonic acid {2,4-difluoro-3- [5- (2-methoxypyrimidin-5-yl) -1H-pyrrolo [2,3-b] pyridine-3-carbonyl] -phenyl} -amide Propane-1-sulfonic acid [3- (5-cyano-1H-pyrrolo [2,3-b] pyridine-3-carbonyl) -2,4-difluorophenyl] -amide, propane-1-sulfonic acid [3 -(5-cyano-1H-pyrrolo [2,3-b] pyridine-3-carbonyl) -2-fluorophenyl] -amide, N- [3- (5-cyano-1H-pyrrolo [2,3-b] ] Pyridine-3-carbonyl) -2,4-difluorophenyl] -2,5-difluorobenzenesulfonamide, N- [3- (5-cyano-1H-pyrrolo [2,3-b] pyridine-3-carbonyl -2, -Difluorophenyl] -3-fluorobenzenesulfonamide, pyrrolidine-1-sulfonic acid [3- (5-cyano-1H-pyrrolo [2,3-b] pyridine-3-carbonyl) -2,4-difluorophenyl] -Amide, N, N-dimethylaminosulfonic acid [3- (5-cyano-1H-pyrrolo [2,3-b] pyridine-3-carbonyl) -2,4-difluorophenyl] -amide, and salts thereof, The formulation, its conjugate, its derivative, its form and its use are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof and forms thereof are active against at least one Raf protein kinase. In addition, diseases and conditions associated with the activity of Raf protein kinase (including melanoma, glioma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer and biliary tract cancer). Also described are methods of its use for treating. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016520131-A |
| priorityDate | 2009-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 975.